Please assess the completion status of the following clinical trial:

Trial Title: A Study of Vemurafenib in Participants With Metastatic Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with Histologically confirmed metastatic melanoma (surgically incurable and unresectable Stage IIIC or Stage IV; AJCC) with BRAF V 600 mutation determined by Cobas 4800 BRAF Mutation Test. Unresectable Stage IIIC disease must have had confirmation from a surgical oncologist~* Participants with either measurable or non-measurable disease according to Response Evaluation Criteria in Solid Tumours (RECIST) Version 1.1~* Participants may or may not have received prior systemic therapy for metastatic melanoma~* Eastern Cooperative Oncology Group (ECOG) performance status between 0 to 2~* Adequate hematologic, renal and liver function~Exclusion Criteria:~* Evidence of symptomatic central nervous system (CNS) lesions, use of steroids or anti-seizure medications for treatment of brain metastases prior to the first administration of vemurafenib~* Previous malignancy (other than melanoma) within the past 2 years, except for treated and controlled basal or squamous cell carcinoma of the skin or carcinoma in-situ of the cervix~* Concurrent administration of any anti-cancer therapies other than those administered in the study~* Clinically significant cardiovascular disease or event within the 6 months prior to first administration of study drug~* Refractory nausea or vomiting, external biliary shunt, or significant bowel resection that would preclude adequate absorption

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vemurafenib (Type: EXPERIMENTAL): Participants will receive vemurafenib at a dose of 960 milligrams (mg) twice daily (bid) until the development of progressive disease, unacceptable toxicity, consent withdrawal, protocol violations endangering participant's safety, death, or study termination by the Sponsor, whichever occurs first.

Based on this trial design, predict the completion outcome and termination type (if applicable).